HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 118.07% from the stock’s previous close.

Armata Pharmaceuticals Price Performance

ARMP stock opened at $3.21 on Wednesday. Armata Pharmaceuticals has a 1-year low of $1.07 and a 1-year high of $5.26. The firm has a market cap of $116.04 million, a price-to-earnings ratio of -1.62 and a beta of 0.96.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. The business had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.68 million. Equities research analysts predict that Armata Pharmaceuticals will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC boosted its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,777 shares of the company’s stock after acquiring an additional 14,647 shares during the period. SeaCrest Wealth Management LLC owned about 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent quarter. 3.57% of the stock is owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.